Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies

Area of Science:

• Cardiology
• Neurology
• Metabolic Disease

Background:

• Heart failure (HF) is frequently accompanied by comorbidities like hypertension, diabetes, and obesity.
• Neurohormonal imbalance and systemic inflammation are key pathomechanisms in HF and its comorbidities.
• Current pharmacological HF treatments effective for reduced ejection fraction show limited benefit in preserved ejection fraction.

Purpose of the Study:

• To review novel device-based therapies for cardiometabolic disease.
• To explore neuromodulation of extra-cardiac targets for HF treatment.
• To address treatment gaps in HF with preserved ejection fraction.

Main Methods:

• Review of existing literature on device-based therapies.
• Focus on neuromodulation strategies targeting extra-cardiac systems.
• Analysis of therapeutic approaches for cardiometabolic disease in HF.

Main Results:

• Identification of emerging device-based therapies.
• Highlighting the potential of neuromodulation for HF and comorbidities.
• Discussion of therapeutic avenues beyond traditional neurohormonal blockade.

Conclusions:

• Device-based neuromodulation offers a promising new frontier for managing cardiometabolic disease in HF.
• Extra-cardiac neuromodulation presents a potential strategy to overcome limitations of current HF pharmacotherapy.
• Further research into these novel therapies is warranted for improved patient outcomes.